Начало › Рак на белия дроб с недребноклетъчен тип › Калифорния › Sacramento
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Sacramento, CA
29 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Sacramento (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Kaiser Permanente Downtown Commons, Sacramento
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- и още 1
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Набиране на участнициФаза 3
- UC Davis Comprehensive Cancer Center ( Site 3204), Sacramento
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Набиране на участнициФаза 3
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 3
- Buhler Specialty Pavilion, Sacramento
- Sutter Medical Center, Sacramento Infusion Center, Sacramento
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- UC Davis Comprehensive Cancer Center, Sacramento
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Набиране на участнициФаза 3
- University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Набиране на участнициФаза 1/2
- UC Davis Comprehensive Cancer Center, Sacramento
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Набиране на участнициФаза 2
- UC Davis Cancer Center (Data Collection Only), Sacramento
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- UC Davis Comprehensive Cancer Center, Sacramento
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Набиране на участнициФаза 1/2
- University of California Davis Comprehensive Cancer Center, Sacramento
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Набиране на участнициФаза 3
- University of California Davis Comprehensive Cancer Center, Sacramento
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Набиране на участнициФаза 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Набиране на участнициФаза 1
- University of California Davis Comprehensive Cancer Center, Sacramento
- University of California, Davis Medical Center, Sacramento
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
Набиране на участници
- University of California, Davis, Sacramento
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Набиране на участнициФаза 1/2
- UC Davis, Davis Comprehensive Cancer Center, Sacramento
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Набиране на участнициФаза 3
- Sutter Institute for Medical Research, Sacramento
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Kaiser Permanente Downtown Commons, Sacramento
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- University of California, Davis Comprehensive Cancer Center, Sacramento
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Набиране на участнициФаза 1
- University of California Davis, Sacramento
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2/3
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набиране на участнициНаблюдателно проучване
- Kaiser Permanente Downtown Commons, Sacramento
- Mercy Cancer Center - Sacramento, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
- и още 1
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
Набиране на участнициФаза 1
- The University of California Davis Comprehensive Cancer Center, Sacramento
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
Набиране на участнициФаза 1
- The University of California Davis Comprehensive Cancer Center, Sacramento
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Набиране на участнициФаза 1/2
- VA Northern California Health Care System, Mather, CA, Sacramento
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Набиране на участнициФаза 1
- University of California-Davis, Sacramento
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY121 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH57 проучвания
- Washington, DC55 проучвания
Други проучвания в Sacramento
- Рак на белия дроб22 проучвания
- Рак на гърдата20 проучвания
- Рак на простатата19 проучвания
- Метастатичен рак16 проучвания
- Остра миелоидна левкемия12 проучвания
- Сърдечна недостатъчност12 проучвания
- Рак на панкреаса12 проучвания
- Рак (всички видове)11 проучвания
- Рак на дебелото черво11 проучвания
- Рак на пикочния мехур10 проучвания
- Колоректален рак10 проучвания
- Диабет тип 29 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.